Neuromuscular junction (NMJ) (NMJ)

The spinal motoneurons and the neuromuscular junction (NMJ) represent the essential interface between the nervous system and skeletal muscles, facilitating voluntary and involuntary movement (StatPearls, 2023). Spinal motoneurons, located in the ventral horn of the spinal cord, transmit electrical impulses via their axons to the NMJ, where the neurotransmitter acetylcholine is released into the synaptic cleft to trigger muscle contraction (NIH, 2022). This complex is the primary site of pathology in various neuromuscular diseases, such as Amyotrophic Lateral Sclerosis (ALS), where motoneurons degenerate, and Myasthenia Gravis, where synaptic transmission is impaired by autoantibodies (Nature Reviews Disease Primers, 2017; Lancet Neurology, 2019). Pharmacological agents targeting this system include neuromuscular blockers used in anesthesia, acetylcholinesterase inhibitors for symptomatic treatment of weakness, and advanced gene therapies like antisense oligonucleotides for Spinal Muscular Atrophy (FDA, 2023; PubChem, 2024). Given its critical role in respiratory function, therapeutic manipulation of the NMJ and motoneurons carries significant risks, including the potential for fatal respiratory failure or profound muscle weakness (StatPearls, 2023).

Other names

Motor end plateMyoneural junctionSpinal motor neuronsVentral horn cellsAlpha motor neuronsSpinal motoneurons / neuromuscular junction

Inhibition of acetylcholinesterase to increase acetylcholine levels, antagonism of nicotinic acetylcholine receptors to induce muscle relaxation, and modulation of SMN2 gene splicing to increase survival motor neuron protein levels.